Key result
Dabigatran achieves expected drug levels without bleeding in a patient on antiretroviral therapy.
Why the study?
Compatibility of novel oral anticoagulants in patients with HIV taking combined antiretroviral therapy has not been established, with no published reports of successful concurrent use.
Is dabigatran safe and well-tolerated in a patient with HIV taking combined antiretroviral therapy?
Case Report (n=1)
Is dabigatran safe and well-tolerated in a patient with HIV taking combined antiretroviral therapy?
This case suggests that dabigatran may be a viable and safe anticoagulation option for selected patients with HIV taking combined antiretroviral therapy.
No takes yet. Share an insight, caveat, or question.
Should not change practice based on single case; hypothesis-generating for dabigatran in HIV on antiretroviral therapy.
Perram et al. (2015) conducted a case report in Treated HIV and non-valvular atrial fibrillation (n=1). Dabigatran was evaluated on Dabigatran blood levels and adverse outcomes (bleeding). Dabigatran was tolerated in a patient with HIV on combined antiretroviral therapy, achieving expected blood levels without bleeding or other adverse outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: